Takeda Pharmaceutical has received U.S. regulatory approval for ORZEYFUL to treat adult narcolepsy type 1, while also issuing new impairment guidance and reaffirming its fiscal 2027 earnings outlook. The stock trades at ¥5,582, with a 7-day return of 5.6% and a year-to-date return of 13.6%. One widely followed fair value estimate places the shares at ¥6,262.69, implying a 10.9% discount, while a separate discounted cash flow model suggests a fair value of ¥14,670.75, a 62% discount to the current price. The approval and guidance updates come as Takeda navigates the anticipated moderation of VYVANSE generic erosion after fiscal 2025, which is expected to allow core growth and launch products to drive a recovery in revenue and earnings.
Takeda Pharmaceutical Co. Ltd.US approval of ORZEYFUL for narcolepsy type 1 is a regulatory win, and reaffirmed fiscal 2027 outlook supports recovery.
